A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

NCT02597049 · Completed

Last updated 2026-05-28

This clinical trial tested the medication dulaglutide in adults with type 2 diabetes to see how it affects blood sugar levels over 24 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 424 people

Who can join Ages 18+ · all sexes

Timeline Started 2015-11 · est. completion 2017-02

Where 41 sites · Austria, Czechia, Germany, Hungary, Israel, Mexico, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT02597049 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC
SGLT2 inhibitor also known as Canagliflozin, Dapagliflozin, Empagliflozin Drug

Administered orally as standard of care for type 2 diabetes
Metformin Drug

Administered orally as standard of care for type 2 diabetes

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02597049 ↗